Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Etoricoxib

Catalog No: tcsc1047

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
202409-33-4

Formula:
$C_{18}H_{15}ClN_2O_2S$

Pathway:
Immunology/Inflammation

Target:
COX

Purity / Grade:
>98%

Solubility:
DMSO : 100 mg/mL (278.68 mM; Need ultrasonic)

Alternative Names:
MK-0663;L-791456

Observed Molecular Weight:
358.84

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active **COX-2** inhibitor, with **IC_{50}**s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

IC50 & Target: IC50: 1.1 μM (COX-2, in human whole blood), 116 μM (COX-1, in human whole blood)[1]

In Vitro: Etoricoxib (MK-0663) is a selective and orally active COX-2 inhibitor, with IC_{50}s of 1.1 μM, 116 μM and 5 μM for COX-2, COX-1 in human whole blood and purified human COX-2, respectively. Etoricoxib (MK-0663) shows inhibitory effect on PGE2 production by CHO (COX-2) cells (IC_{50}, 79 nM), on purified human COX-2 with detergent (IC_{50}, 4.1 μM), and on purified PGE2 production by U937 microsomes (low substrate; IC_{50}, 12.1 μM). However, Etoricoxib (MK-0663) has little activity against COX-1 with a K_i of 167 μM[1].

In Vivo: Etoricoxib (MK-0663) (0.1-30 mg/kg, p.o.) dose-dependently inhibits carrageenan-induced paw edema, carrageenan-induced paw hyperalgesia, and endotoxin-induced pyresis in rats. Etoricoxib (≥10 mg/kg) completely reverses hyperalgesia response in the rat hyperalgesia model. Etoricoxib (MK-0663) (200 mg/kg/day) has no effect on urinary ^{51}Cr excretion in rats, and nor in monkeys at 100 mg/kg/day[1]. Etoricoxib (MK-0663) (50 and 100 mg/kg) potently increases the malondialdehyde (MDA) and myeloperoxidase (MPO) levels, and decreases the total glutathione (tGSH) and glutathione reductase (GSHRd) levels in rats. Etoricoxib (MK-0663) (100 mg/kg) significantly inhibits the decrease of NO in rats[2]. Etoricoxib (MK-0663) (0.64 mg/kg, p.o.) reduces the features such as multiple plaque lesions, hyperplasia and dysplasia induced by 1,2-dimethylhydrazine dihydrochloride (DMH) in rats[3].